Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy.
Preclinical in vivo studies of agents targeted against metastasis have to date been based primarily on end-point assays. Such assays can determine whether a treatment affects the number or size of metastases in an organ at a given time, but are poorly suited to determining how and at what stage in the process the treatment affected the end point. High resolution in vivo videomicroscopy permits direct observation of the process of metastasis as it occurs in living animals over time. Studies based on this technique and a cell accounting procedure we have devised, have shown that early steps in the metastatic process (survival in the circulation, extravasation) contribute relatively little to cell loss and metastatic inefficiency. Steps that occur after extravasation appear to be primarily responsible for the significant losses that result in metastatic inefficiency, and these steps may represent good targets for the design of new antimetastatic therapies. Matrix metalloproteinases have been implicated functionally in metastasis, and are viewed as an appropriate target in the development of inhibitors of metastasis. Using both endogenous and synthetic exogenous metalloproteinase inhibitors, we have shown that the inhibition of metastasis which these agents produce is not due to inhibition of cell extravasation from the circulation into the tissue, but to reduction of angiogenesis within metastases. A similar conclusion was reached concerning the mechanism of action, on metastasis, of carboxyamidotriazole, an inhibitor of calcium-mediated signal transduction which is currently in Phase II single agent clinical trials. In vivo videomicroscopy of sequential steps in metastasis, coupled with methods that allow precise quantification of cell loss at specific steps in the metastatic process, as well as standard histological assessment at stages identified as crucial, allow characterization of the details of metastasis as an ongoing process. This provides a powerful complement to end-point assays, for it allows mechanistic information to be obtained from in vivo experiments, an approach which provides better understanding of how and when a drug may function in vivo to inhibit metastasis.
Chambers
A F
AF
Department of Oncology, University of Western Ontario, London, Canada. achambers@lrcc.on.ca
MacDonald
I C
IC
Schmidt
E E
EE
Morris
V L
VL
Groom
A C
AC
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002642:Chick Embryo; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D008666:Metalloendopeptidases / Q000378:metabolism; D051379:Mice; D018715:Microscopy, Video / Q000379:methods; D008863:Microspheres; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D009363:Neoplasm Proteins / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D009360:Neoplastic Cells, Circulating; D009389:Neovascularization, Pathologic; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D019715:Tissue Inhibitor of Metalloproteinase-1; D014230:Triazoles; C062058:carboxyamido-triazole; D008666:Metalloendopeptidases